Supplier performance metrics give regulated companies the data they need to manage supply chain risk before it reaches the production floor. FDA and ISO 13485 both require organizations to evaluate supplier performance, but neither regulation prescribes a specific set of metrics. The choice of what to measure, and how to use it, separates a supplier program that satisfies auditors from one that actually reduces quality risk.

Why supplier performance measurement is a regulatory requirement

Both FDA 21 CFR Part 820 (now consolidated into the QMSR) and ISO 13485 Section 7.4 require organizations to evaluate and re-evaluate suppliers based on their ability to meet requirements. That evaluation must be documented. The regulation does not list specific metrics, but it is clear that a supplier approval that was completed at onboarding and never revisited does not constitute ongoing evaluation.

ISO 13485:2016 Section 7.4.1 states that organizations must establish criteria for selection, evaluation, and re-evaluation of suppliers, and must maintain records of evaluation results and any necessary actions. A supplier that was qualified five years ago but has delivered three nonconforming lots in the past twelve months represents a documented risk — one that should appear in your supplier performance data and trigger a defined response.

During internal audits and external regulatory inspections, auditors specifically look for evidence that supplier performance is being monitored over time. A supplier scorecard with no data, or a scorecard that shows declining performance with no corresponding corrective action, is a finding waiting to be written.

The core supplier performance metrics for regulated industries

The following metrics cover the dimensions of supplier performance most relevant to quality, delivery, and compliance in regulated industries. Not every organization tracks all of them, but the combination you choose should reflect the actual risk profile of your supply base.

On-time delivery rate

On-time delivery measures the percentage of purchase orders fulfilled within the agreed delivery window. Delivery failures create production disruptions, but in regulated environments they create something more serious: pressure to use materials before incoming inspection is complete, or to expedite reviews that should not be expedited. A supplier with consistently late deliveries creates operational conditions that increase quality risk, even when the material itself is conforming.

Track on-time delivery as a rolling percentage over a defined period — typically quarterly. Set a threshold below which a supplier is flagged for review, and document the threshold in your supplier quality procedure.

Incoming inspection rejection rate

The rejection rate measures what percentage of incoming lots fail to meet acceptance criteria at receiving inspection. This is one of the most direct indicators of supplier quality. A supplier with a rejection rate above your threshold should trigger a Supplier Corrective Action Request (SCAR) and potentially a re-evaluation of their approved status.

Track rejection rate by lot (percentage of lots rejected) and by unit (percentage of units rejected within inspected lots). The two numbers tell different stories — a low lot rejection rate can mask a high unit rejection rate if the lots that fail tend to fail badly.

Nonconformance rate (PPM or percentage)

Parts Per Million (PPM) nonconformance is a standard metric in regulated manufacturing. It measures the number of nonconforming units per million units received, which allows meaningful comparison across suppliers and product types that ship in very different quantities. For high-volume components, PPM is more informative than a simple rejection percentage. For low-volume specialty components, a percentage is usually more practical.

SCAR issuance and closure rate

The number of Supplier Corrective Action Requests issued to a supplier over a defined period, and the percentage closed on time, are both important signals. A supplier that receives frequent SCARs but closes them promptly and with verified effectiveness is behaving differently from one that receives the same number of SCARs and repeatedly misses closure deadlines or provides ineffective responses.

SCAR closure rate should be tracked separately from SCAR effectiveness. A SCAR that is closed on time but whose corrective action did not prevent recurrence has not actually solved the problem.

Certificate of Conformance (CoC) accuracy

For incoming materials that rely on supplier-provided certificates of conformance, tracking the accuracy of those certificates against the actual test results is a meaningful quality indicator. A supplier whose CoCs consistently reflect the actual material characteristics is easier to trust than one whose certificates require routine verification. CoC accuracy issues can indicate problems with the supplier’s internal quality controls or documentation practices.

Audit findings

If your organization conducts supplier audits, the findings from those audits should feed into the supplier performance record. Track the number and severity of findings per audit cycle, the percentage of findings closed on time, and whether repeat findings appear across audit cycles. A supplier that receives the same finding in consecutive audits has not addressed the underlying issue.

Regulatory compliance status

For suppliers of regulated materials or components, their own regulatory status is a performance indicator. An FDA-registered facility that receives a Warning Letter, or a supplier whose certifications have lapsed, represents a supply chain risk that should trigger re-evaluation regardless of their delivery and quality numbers. Monitor the FDA registration and certification status of critical suppliers as part of your ongoing evaluation process.

How to build a supplier scorecard

A supplier scorecard consolidates the metrics above into a single periodic performance summary. The goal is a consistent format that allows comparison across suppliers and over time, and that makes escalation decisions straightforward.

Effective scorecards share a few common design characteristics. They use weighted metrics rather than simple averages — delivery may be worth 20% of the overall score for a commodity supplier but 5% for a supplier of a sole-source critical component where quality is everything. The weighting should reflect your organization’s actual risk priorities. Document the weighting in your supplier quality procedure so it is not adjusted on a case-by-case basis.

Scorecards should be calculated on a fixed cadence — typically monthly or quarterly — and shared with the supplier. Sending a supplier a scorecard that shows deteriorating performance, with no action taken and no communication to the supplier, satisfies neither the spirit of continuous improvement nor the expectations of a regulatory inspector. The scorecard is most useful when it is the basis for a regular performance dialogue with the supplier.

Thresholds should be defined in advance. A score below a defined threshold should trigger a specific response: a SCAR, an on-site audit, a probationary status, or removal from the Supplier Quality Management approved list. The threshold and the response should be documented, not improvised.

Connecting supplier metrics to CAPA and risk management

Supplier performance data should feed into your broader quality system, not sit in a separate spreadsheet that no one looks at between scorecarding periods. The connection points that matter most are CAPA and risk management.

When a supplier metric crosses a threshold, a deviation CAPA or SCAR should be initiated in your QMS. The record should reference the specific metric that triggered the action and the performance data supporting it. This creates the traceability that regulators expect: the same nonconformance data that appears in the scorecard should appear in the CAPA record.

For risk register purposes, suppliers of critical components or materials should have a risk profile that is updated based on their performance data. A supplier whose rejection rate doubles in a single quarter represents an increased supply chain risk, and that risk should be visible in your risk management process even if no individual nonconforming lot has yet caused a production or patient impact.

Common failures in supplier performance programs

Most supplier performance programs in regulated companies share the same set of weaknesses. Knowing them makes it easier to avoid them.

Metrics are collected but not acted on. The scorecard is calculated, the data exists, but nothing happens when a supplier falls below threshold. This creates a paper record of known problems with no documented response — exactly the pattern a regulatory inspector will highlight.

Scorecards are not shared with suppliers. The supplier never sees their performance data, receives no feedback, and has no reason to improve. Performance-based supplier management requires communication, not just internal tracking.

Metrics are not linked to approved supplier status. The organization tracks performance but does not connect it to any decision about the supplier’s continued approval. A supplier on the approved list with two consecutive years of declining performance scores and no re-evaluation does not represent a functioning supplier quality program.

Historical data is not retained. The organization overwrites or discards old scorecard data rather than maintaining a historical record. Without trend data, you cannot demonstrate continuous evaluation, and you cannot detect slow deterioration in supplier performance.

How a digital QMS automates supplier performance tracking

Tracking supplier performance manually, across multiple suppliers and multiple metrics, is labor-intensive and error-prone. A digital QMS integrates the data sources — receiving inspection results, SCAR records, audit findings, CoC verification logs — and calculates scorecard metrics automatically.

Cloudtheapp’s platform includes Supplier Quality Management as one of 60+ pre-built applications for quality, safety, and compliance. The supplier module links incoming inspection results, SCAR issuance and closure, audit records, and approved supplier list status in a single system. Scorecards can be generated automatically on a defined cadence. When a supplier metric crosses a defined threshold, the system can trigger a workflow — creating a SCAR or flagging the supplier for re-evaluation — without manual intervention.

Every data point in the system is part of an audit trail. When an inspector asks to see how you evaluated supplier X over the past two years, the data is in one place, complete, and traceable from receiving inspection record to SCAR to corrective action to scorecard update.

To see how this works for your supply base, schedule a demo with the Cloudtheapp team.

Using supplier performance data in management review

ISO 13485 Section 5.6 requires that management review inputs include information on supplier and subcontractor performance. This is where the supplier scorecard connects to executive decision-making. The data you have been collecting throughout the year becomes the basis for decisions about supplier development investment, dual sourcing, inventory buffering, or supplier removal.

Management review is also where trends that are below the threshold for individual SCAR triggers can still be surfaced. A supplier whose scores have been declining gradually — still above threshold but moving in the wrong direction — warrants attention before they reach the point of triggering a formal corrective action. The management review is the right forum for that conversation, and the scorecard data provides the factual basis for it.

Conclusion

Supplier performance metrics are the operational foundation of a functioning supplier quality program. The metrics themselves are straightforward. What separates a compliance checkbox from a genuine quality tool is what happens with the data: whether thresholds trigger real responses, whether suppliers receive feedback, whether declining performance shows up in risk decisions, and whether the historical record is complete enough to show an inspector that the organization has been paying attention. A digital QMS makes that process systematic rather than heroic.

This post created by and appeared first on Cloudtheapp

A Material Review Board (MRB) is the cross-functional body that decides what happens to nonconforming material — accept, rework, scrap, or return to supplier. FDA requires documented disposition decisions under 21 CFR Part 820 (QMSR), and ISO 13485 imposes similar requirements under Section 8.3. Without a functioning MRB process, your quality system will accumulate unauthorized dispositions, undocumented deviations, and the kind of record gaps that generate FDA Form 483 observations during inspections.

What is a Material Review Board?

A Material Review Board is a cross-functional committee authorized to evaluate nonconforming material and make binding disposition decisions. The board typically includes members from quality assurance, engineering, manufacturing, regulatory affairs, and procurement. The exact combination varies by organization size and the nature of the nonconformance.

The MRB is not an ad hoc committee. It operates within a documented procedure, with defined roles, quorum requirements, and required signatures. Every decision the MRB makes must be traceable, appearing in an audit trail that regulators can follow from initial detection of the nonconformance through to final disposition and any associated corrective action.

In some organizations, the MRB is also called a Material Review Committee (MRC). The name is secondary. What matters is that the function exists, the authority is defined, and the records are complete.

Why the MRB process matters under FDA regulation

Under 21 CFR Part 820, now consolidated into the Quality Management System Regulation (QMSR) aligned with ISO 13485, manufacturers of medical devices must maintain documented procedures for identifying, documenting, evaluating, segregating, and disposing of nonconforming product. The regulation does not prescribe the exact structure of an MRB, but it requires that anyone who authorizes a disposition decision is qualified and that the decision itself is documented.

According to a white paper published by Pathwise on nonconforming materials compliance, inadequate procedures for nonconforming product appeared among the top ten most frequently cited observations on FDA Form 483 inspections based on FDA FY2015 Inspectional Observation Summaries. [Source: Pathwise] That pattern has persisted. The MRB is where those inadequacies most often originate — because the process is undocumented, the review team is not qualified, or the disposition decisions lack the justification a regulator expects to see.

ISO 13485 Section 8.3 states that organizations must identify and control nonconforming product to prevent its unintended use or delivery. The standard requires documented procedures defining responsibilities for review and disposition. For organizations pursuing ISO 13485 certification or maintaining FDA compliance, the MRB procedure is not optional.

The four disposition options

When the MRB reviews a nonconforming material or product, it has four disposition paths available. Each carries specific documentation and, in some cases, regulatory notification requirements.

Accept as-is

The MRB determines that the nonconformance does not compromise safety, identity, strength, purity, or quality, and that the product is fit for its intended use despite falling outside specification. This decision requires documented technical justification. For medical devices, use-as-is disposition for product that has already left the facility may trigger MDR reporting obligations depending on the nature of the nonconformance. The justification must be in writing, signed by authorized personnel, and linked to the original nonconformance record.

Rework or repair

The nonconforming material can be brought back into conformance through a defined rework process. Rework must itself be controlled — it needs a procedure, personnel qualification records, and post-rework inspection documentation confirming the product meets specification after rework is complete. Reworked product should be re-inspected and re-tested before release. The rework process must not introduce new risks.

Scrap

The material is destroyed or rendered unusable and disposed of in a controlled manner. Scrap decisions still require documentation — including what was scrapped, how much, why, and how the physical destruction was controlled. This prevents scrapped material from re-entering the supply chain.

Return to supplier

Nonconforming incoming material is returned to its source. This disposition typically initiates a root cause investigation on the supplier’s side and may require a Supplier Corrective Action Request through your Supplier Quality Management process. The MRB record should document the return authorization, the supplier notification, and any commitments on corrective action timelines.

Who sits on the MRB

The composition of the MRB depends on what type of nonconformance is being reviewed. A minor dimensional deviation on a purchased component may need only quality and engineering. A sterility failure in a finished medical device requires quality, regulatory, manufacturing, and potentially the design authority.

The procedure should define the minimum required attendees for different categories of nonconformance and who has signature authority — meaning who can formally approve a disposition decision. At minimum, quality assurance must be represented and must concur with every disposition. Engineering input is required when the decision involves technical acceptance criteria or rework feasibility. Regulatory affairs is required when the nonconformance has a potential safety or reporting implication.

Ad hoc decisions made outside the defined process — someone verbally approving a disposition on the production floor without a written record — are exactly what generates 483 observations. The entire point of the MRB is to create a controlled, traceable decision pathway.

What the MRB record must contain

The FDA requires that nonconforming product handling be fully documented. An MRB record that will survive an inspection should include the following:

• A unique identifier for the nonconformance
• Description of the product or material, including lot number, quantity, and location
• Description of the nonconformance — what specification was not met and how the deviation was detected
• Names and roles of MRB members who participated in the review
• The disposition decision with written technical justification
• Signatures of authorized reviewers and the date of each signature
• Whether a CAPA was initiated as a result of the disposition
• Disposition completion date and confirmation of physical handling (scrap certificate, rework inspection results, return shipping records)

For use-as-is dispositions, the technical justification must be especially detailed. Inspectors look for specificity: what risk assessment was performed, what data supported the decision, and who had the authority to accept the product outside specification.

Common MRB failures that generate 483 observations

Most MRB-related 483 observations fall into a few recurring patterns. Knowing them makes it easier to design a process that avoids them.

No documented procedure. The organization handles nonconforming material but has no written MRB procedure defining roles, responsibilities, quorum, and decision criteria. This is a direct 820.90 / QMSR violation.

Incomplete records. The disposition decision is recorded but the technical justification is absent, signatures are missing, or the link between the nonconformance and any resulting corrective action is broken. Inspectors follow the paper trail. Gaps in it raise questions.

Unauthorized dispositions. Someone without defined authority approves a disposition. This happens when the formal MRB process is bypassed under production pressure. The procedure must define who has authority, and that authority must be exercised formally.

No segregation. Nonconforming material is not physically separated from conforming product while awaiting MRB review. If nonconforming material can mix with released product, the control system has failed at a fundamental level.

No CAPA linkage. The nonconformance is dispositioned but no systemic corrective action is initiated for recurring issues. A pattern of use-as-is decisions on the same nonconformance with no CAPA will draw scrutiny from any auditor reviewing the trend data.

How a digital QMS strengthens the MRB process

Paper-based MRB processes introduce delays and documentation risks that a modern eQMS removes. When a nonconformance is detected in a paper system, someone physically walks the form to each MRB member, collects signatures, and files the completed record. That process is slow, easy to lose track of, and difficult to audit in real time.

A digital QMS automates the MRB workflow. When a nonconformance is created, the system routes it to the appropriate reviewers based on product type, nonconformance category, and defined quorum rules. Each reviewer receives a notification, reviews the record in the system, and applies an electronic signature. The audit trail is automatic — every view, comment, and approval is timestamped and attributed. When a CAPA is required, the system links the two records permanently.

Cloudtheapp includes Nonconforming Material and Supplier Quality Management as part of a platform with 60+ pre-built quality, compliance, and operations applications. The Nonconforming Material module supports full MRB workflow routing, disposition tracking, and CAPA linkage, with electronic signatures that meet 21 CFR Part 11 requirements. Inspectors who request nonconforming product records find a complete, searchable history — no missing signatures, no ambiguous dispositions.

To see how this works in practice, schedule a demo with the Cloudtheapp team.

MRB in the context of audits and continuous improvement

The MRB does not operate in isolation. Its outputs feed directly into the broader quality system. Every disposition generates data — what failed, how often, at what stage of production, from which supplier. When that data is trended, it becomes the raw material for systemic improvement.

During internal audits, quality teams should review MRB records as a leading indicator of systemic problems. A pattern of repeat nonconformances with use-as-is dispositions and no corresponding CAPA signals that the organization is managing symptoms rather than root causes. Internal and external auditors will interpret that pattern the same way.

When a nonconformance warrants corrective action, the deviation CAPA record should reference the originating MRB decision so that anyone reviewing the CAPA later understands the full context. This linkage is the kind of traceability that regulators expect in a mature quality system.

Setting up a compliant MRB procedure

If your organization lacks a formal MRB procedure, or if the existing one has gaps, here is where to start.

Define scope. The procedure should specify what triggers an MRB review. Some organizations use a tiered system where minor deviations go through a streamlined single-reviewer approval and major or safety-related nonconformances go to the full board. Document the criteria for each tier.

Define membership and authority. Name the roles, not necessarily specific individuals, that must be represented at each tier. Define who can authorize each disposition type. Use-as-is and scrap may carry different authority requirements.

Define the record format. Whether you use a digital system or a controlled paper form, the record format should be defined in the procedure and all required fields should be explicit.

Define timelines. Nonconforming material should not sit unreviewed for weeks. Set maximum review timelines by nonconformance category and build in escalation paths when reviews are not completed on time.

Connect to trending. The MRB procedure should reference how nonconformance data is compiled, analyzed, and reported, whether monthly, quarterly, or at management review. A deviation report on a recurring nonconformance without trend data attached is a missed opportunity for systemic improvement.

Conclusion

The Material Review Board is one of the most operationally visible parts of a quality system. It is where nonconforming material gets reviewed, documented, and decisively handled, or where the process breaks down under production pressure and creates the documentation gaps that inspectors find later. A well-designed MRB procedure, supported by a digital QMS that enforces workflow and captures every step automatically, removes the manual friction and the compliance risk. The records are complete. The decisions are traceable. The audit trail holds.

This post created by and appeared first on Cloudtheapp

If you have spent any time in a regulated industry, you have heard the phrase “computer system validation” repeated in audits, vendor conversations, and implementation projects. You have probably also sat through presentations where the acronyms piled up faster than the explanations.

This article is a straight translation. No jargon without a definition. No regulatory language without a plain-English equivalent. By the end, you will know exactly what IQ, OQ, and PQ mean, why they exist, and what they actually look like in practice when you are deploying a quality management system.

Why Computer System Validation Exists

The short version: the FDA does not trust software that has not been proven to do what it claims to do.

That sounds obvious, but the implication is significant. If your quality management system records CAPA closures, document approvals, or batch records, those records carry regulatory weight. An FDA investigator reviewing your data assumes that your system produced accurate, complete, and unaltered records. Validation is the body of evidence that supports that assumption.

Without validation, your system is an assertion. With validation, it is a documented proof.

This is codified in FDA 21 CFR Part 820 (the Quality System Regulation for medical devices), 21 CFR Part 11 (the electronic records and signatures rule), and broader cGMP expectations for pharmaceutical manufacturers. All of them require that software used in regulated activities be validated before use.

The Validation Package: What It Contains

A validation package is a structured set of documents that collectively prove a system works as intended, was installed correctly, and has been tested under conditions that reflect how it will actually be used.

A complete validation package contains the following:

Validation Plan : The master document that defines the scope, approach, methodology, roles, and acceptance criteria for the entire validation effort. It is written before any testing begins and approved before execution starts.

User Requirements Specification (URS) : A document that captures what the system must do from the perspective of the end user. Every requirement in the URS must be traceable to a test. If a requirement cannot be tested, it should not be in the URS.

Installation Qualification (IQ) : Evidence that the system was installed correctly in the intended environment.

Operational Qualification (OQ) : Evidence that the system operates as specified under normal and edge-case conditions.

Performance Qualification (PQ) — Evidence that the system performs consistently under real-world use conditions.

Traceability Matrix : A table that maps every requirement in the URS to the specific test that verifies it. This is the document an FDA investigator uses to confirm that nothing was skipped.

Summary Report — A final document that summarizes the validation effort, records the outcome of all testing, documents any deviations encountered, and states whether the system is approved for use.

IQ: Installation Qualification

What it means in plain English: Did we install the software correctly, in the right environment, with the right configuration?

IQ is verification, not testing. It confirms that the system arrived in the state it was supposed to arrive in. For a cloud-based SaaS platform like Cloudtheapp, IQ addresses questions such as:

• Is the system hosted on the correct infrastructure (AWS, in this case)?
• Are the correct software versions in place?
• Are user roles and access controls configured as specified?
• Is data transmission occurring over encrypted connections?
• Are audit trails enabled and functioning?

IQ does not test features. It confirms the foundation is correct before functional testing begins. An IQ that fails, for example, because a configuration setting was missed or the wrong environment was provisioned, means no OQ testing should proceed until the IQ issue is resolved and documented.

What the IQ document looks like: A series of checklist-style verification steps, each with an expected result, an actual result, a pass/fail notation, and a tester signature. Every step is traceable back to an IQ requirement in the URS.

OQ: Operational Qualification

What it means in plain English: Does the system do what it is supposed to do when you use it the way it was designed to be used?

OQ is where functional testing happens. It covers the system’s specified behavior across normal operating conditions and deliberate edge cases. For a quality management system, OQ testing would cover scenarios such as:

• A CAPA record is created, routed for approval, and closed. Does the system follow the workflow exactly as configured?
• A document is revised. Does the system enforce version control, require approval before the new version is effective, and archive the prior version with a complete audit trail?
• A user attempts to access a module they are not authorized for. Does the system deny access and log the attempt?
• An electronic signature is applied. Does it capture the signer’s identity, timestamp, and meaning of signature in compliance with 21 CFR Part 11?

OQ tests are scripted in advance. The expected result is documented before the test is executed, so there is no ambiguity about whether the system passed or failed. Any deviation from the expected result is documented as a discrepancy, investigated, resolved, and re-tested before the OQ can be approved.

What the OQ document looks like: A set of test scripts, each with a test objective, prerequisites, step-by-step execution instructions, expected results, actual results, pass/fail notation, and tester and reviewer signatures.

PQ: Performance Qualification

What it means in plain English: Does the system perform consistently when real users are running real workflows under real conditions?

PQ is the final phase of validation and the closest thing to a live simulation. It moves beyond scripted feature testing into end-to-end process verification. Where OQ tests individual functions, PQ tests the system as a whole across the processes it will actually support.

For a quality management system, a PQ scenario might look like: a full CAPA lifecycle from deviation intake through root cause investigation, corrective action assignment, effectiveness check, and closure, executed by the actual users who will own the process after go-live. The PQ confirms that the system supports the workflow as a complete, connected sequence and that the users can execute it correctly with the training they have received.

PQ is also where performance under load is sometimes addressed, confirming that the system responds within acceptable timeframes when multiple users are working simultaneously.

What the PQ document looks like: End-to-end scenario scripts that mirror real business processes, executed by actual end users or process owners, with documented results and sign-off from the process owner and quality function.

The Traceability Matrix: Why It Matters More Than People Think

The traceability matrix is the document that ties everything together, and it is the first thing an experienced FDA investigator will ask to review when evaluating your validation package.

Its purpose is simple: for every requirement in your URS, there must be at least one test that verifies it. The matrix maps each requirement to the specific IQ, OQ, or PQ test that covers it.

Gaps in the traceability matrix are gaps in your validation. A requirement that cannot be traced to a test is a requirement that was never verified. That is a validation finding, and depending on the criticality of the unverified requirement, it can call the entire system’s qualification status into question.

Building the traceability matrix as you build the URS and test scripts, rather than after the fact, is the single most effective way to prevent traceability gaps.

What “Validated by the Vendor” Actually Means

When a SaaS quality management platform states that it ships with a validation package, it means the vendor has already executed IQ and OQ testing against the platform in a reference environment and is providing that documented evidence to customers.

At Cloudtheapp, every platform update ships with a complete validation package: Validation Plan, URS, IQ, OQ, PQ, Traceability Matrix, and Summary Report. This means customers do not need to execute platform-level testing from scratch. They review and approve the vendor-supplied package, then focus their own validation effort on their specific configuration, their workflows, and their PQ scenarios.

This approach significantly reduces the validation burden for each update cycle. Rather than treating every software update as a full re-validation project, customers leverage the vendor package as the foundation and scope their own testing to the delta.

The Most Common Validation Mistakes

After more than twenty six years of working with regulated organizations on CSV implementation, the same gaps appear repeatedly.

Treating IQ as a formality. IQ is often executed quickly because it feels like a checklist exercise. But an IQ that misses a configuration requirement creates a foundation problem that OQ and PQ cannot fix. Take IQ seriously.

Writing OQ scripts after execution. Test scripts must be written and approved before testing begins. Scripts written after the fact are documentation reconstructions, not validation evidence. FDA investigators know the difference.

Skipping PQ or substituting OQ for PQ. OQ proves features work. PQ proves processes work. They are not interchangeable. Regulated organizations that skip PQ often discover during inspection that they validated the system but never validated how their people use it.

Leaving the traceability matrix until the end. Build the matrix as you build the URS. Every requirement should have a test assigned to it before execution begins.

Treating validation as a one-time event. A validated system that changes must be re-validated to the extent of the change. Change control and validation are connected. If your change management process does not include a step to assess validation impact, it is incomplete.

What Audit-Readiness Looks Like

An audit-ready validation package is not just technically correct. It is organized, accessible, and navigable by someone who did not build it.

Every document should be version-controlled, approved with electronic or wet-ink signatures, and stored where it can be retrieved in minutes, not hours. The traceability matrix should be current, meaning it reflects the system as it exists today, not as it existed at the time of the original validation. Any post-validation changes should be documented through formal change control with an assessment of validation impact and re-testing executed where required.

If an FDA investigator walked in today and asked for your CSV package for your quality management system, how long would it take to produce it? The answer to that question is a reasonable proxy for the actual state of your validation program.

Computer system validation is a documentation discipline as much as a technical one. The underlying principle is straightforward: if a regulated system produces records that carry compliance weight, the organization must be able to prove the system works correctly. IQ, OQ, and PQ are the structured framework for building and preserving that proof.

If you are evaluating a cloud QMS and want to understand what the vendor-side validation package covers, or if your current system is creating more validation overhead than it should, reach out to the Cloudtheapp team for a walkthrough.

This post created by and appeared first on Cloudtheapp

Under the FDA's Quality Management System Regulation (QMSR), effective February 2, 2026, corrective action and preventive action are two distinct, separately evaluated QMS processes with different triggers, different documented inputs, and different required outputs. Corrective action responds to a confirmed nonconformity; preventive action responds to a potential failure identified through data analysis before any event occurs. FDA investigators now assess these processes independently under Compliance Program 7382.850. Organizations that still operate a single merged CAPA SOP, treating preventive action as a follow-on step inside a corrective action record, carry measurable inspection risk under the current regulatory framework.

What QMSR Changed for CAPA

The Quality Management System Regulation (QMSR), which became effective on February 2, 2026, is a substantive overhaul of 21 CFR Part 820. It harmonizes FDA's medical device quality requirements with ISO 13485:2016 by incorporating that standard by reference, creating a dual-layer regulatory obligation: manufacturers must comply with both the QMSR's specific statutory requirements and the entirety of ISO 13485:2016.

For CAPA practitioners, the implications are significant. Under the legacy Quality System Regulation (QSR), section 820.100 addressed “Corrective and Preventive Action” as a single combined process. The language was broad enough that industry practice largely treated corrective and preventive action as two phases of the same workflow. A nonconformance would trigger a CAPA record, a root cause investigation would be conducted, corrective actions would be assigned, and then a “preventive action” field would be populated, often describing steps to prevent recurrence of the same event. This blending was not FDA's original intent, but the structure of section 820.100 allowed it to persist for decades.

In the QMSR preamble, Comment #20 makes the FDA's position explicit: the agency's intent was always that corrective action and preventive action function as ISO 13485:2016 defines them, as separate processes with distinct triggers, inputs, and documentation requirements. QMSR removes the regulatory ambiguity. ISO 13485:2016 addresses corrective action in clause 8.5.2 and preventive action in clause 8.5.3. These are independent QMS processes with separate procedural requirements, not sub-steps of a unified workflow.

FDA investigators conducting inspections under Compliance Program 7382.850 now evaluate each process on its own terms. An organization that runs both through one SOP is not automatically in violation, but the documentation that process generates must satisfy the distinct requirements of each clause independently. In practice, that outcome is difficult to achieve with a single-form CAPA record.

Corrective Action Under QMSR: What the Regulation Requires

Corrective action, as defined under ISO 13485:2016 clause 8.5.2, is the process of eliminating the root cause of a detected nonconformity to prevent its recurrence. The trigger is always reactive: something has already occurred. A product nonconformity, a complaint, a deviation CAPA, a supplier failure, a failed inspection, an audit finding. In every case, a confirmed adverse condition has been identified, and the corrective action process begins from that documented event.

The standard and the QMSR require that the corrective action procedure produce specific documented evidence. This includes: a review of the nonconformities encountered; a determination of the causes of those nonconformities; an evaluation of the need for action to ensure that nonconformities do not recur; the determination and implementation of the action required; records of the investigation and its results; and verification or validation that the corrective action taken does not adversely affect the ability to meet applicable requirements or the safety and performance of the device.

The root cause investigation is the analytical core of the corrective action process, and it is the element FDA investigators scrutinize most closely. Common inspection findings include: corrective actions that address only the symptom rather than the systemic cause; investigations closed without documented evidence of root cause determination; and effectiveness checks that verify the action was completed rather than verifying the nonconformity did not recur in a defined observation period.

The depth and rigor of the root cause investigation also determines the scope of the corrective action taken. An investigation that identifies “operator error” as the root cause without examining training record completeness, work instruction clarity, or process design factors will typically produce a corrective action that does not hold. FDA warning letters frequently reference situations where the same or similar nonconformity recurred after a closed corrective action record because the underlying root cause was not fully addressed.

Under QMSR, the risk-based approach required throughout ISO 13485:2016 applies directly to corrective action. The extent of investigation and urgency of action must be proportionate to the effect of the nonconformity encountered. A one-off documentation error in a low-risk process may warrant a focused correction and a brief investigation. A recurring product failure with field impact requires a comprehensive investigation, a formal risk assessment, and potentially a systemic process review. Both must be documented, but the calibration must be defensible and traceable.

Preventive Action Under QMSR: A Proactive, Data-Driven Process

Preventive action, defined in ISO 13485:2016 clause 8.5.3, is the process of eliminating the cause of a potential nonconformity to prevent its occurrence. The trigger is always proactive: nothing has happened yet. The preventive action process begins when data or analysis reveals that conditions exist which, if left unaddressed, are likely to produce a nonconformity in the future.

This distinction in trigger is the most operationally important difference between corrective and preventive action, and it is the one most consistently misunderstood in organizations that rely on a merged CAPA procedure. Preventive action does not start after a problem occurs. It starts with data.

The inputs that can initiate a preventive action include: trend analysis of in-process monitoring data; quality metrics that show gradual degradation before reaching a nonconformance threshold; risk assessments that identify high-probability failure modes with insufficient current mitigations; supplier performance data trending toward a potential qualification failure; internal audits or management reviews that surface systemic vulnerabilities; and customer feedback indicating growing dissatisfaction with a characteristic not yet reaching formal complaint status.

ISO 13485:2016 clause 8.5.3 requires organizations to: determine potential nonconformities and their causes; evaluate the need for action to prevent occurrence; determine and implement the action needed; record the results of the investigation; and review preventive actions taken. Critically, information about preventive actions must be submitted as an input to management review. This creates a formal feedback loop between the preventive action process and senior leadership oversight, and it means preventive action activity must be traceable to the management review record.

Under QMSR, FDA now expects to see active preventive action programs during inspections, not just corrective action records. An organization that can only demonstrate reactive CAPA, with no documented preventive actions sourced from trend data, risk analysis, or management review inputs, presents a visible gap. FDA investigators look for evidence that the organization systematically analyzes data beyond direct nonconformances and translates that analysis into documented, time-bound preventive measures.

The Documentation Each Process Requires

Because QMSR and ISO 13485:2016 treat corrective and preventive action as separate processes, the documentation each one produces must be distinct. An FDA Form 483 observation citing inadequate corrective action will be assessed against the specific requirements of clause 8.5.2. A citation for inadequate preventive action will be assessed against clause 8.5.3. A merged CAPA record that combines both must satisfy each set of requirements simultaneously, and the record must clearly demonstrate which portions of the documentation belong to which process.

For corrective action, the minimum required documentation covers: the identified nonconformity and its source; the investigation findings and determined root cause; the corrective actions taken; documentation of the investigation results; evidence of effectiveness verification with defined criteria; and records of any updates to procedures, specifications, or training that resulted from the action.

For preventive action, the minimum required documentation covers: the potential nonconformity identified and its source data; the analysis that established the likelihood of occurrence; the preventive actions taken and their rationale; the results of those actions; and records submitted to management review with traceability back to the source data.

Effectiveness verification deserves particular attention in both processes. For corrective action, the verification confirms that the action taken actually eliminated the root cause and that the nonconformity has not recurred within a defined observation period. The verification method, timing, and pass/fail criteria must be predetermined and documented at the time the corrective action plan is finalized, not assigned retrospectively. For preventive action, effectiveness monitoring confirms that the potential nonconformity has not materialized after the preventive measure was implemented, over a defined observation period assessed against the source data that originally triggered the action.

A chronic inspection finding across both processes is that effectiveness checks are left open indefinitely or closed with narrative notes rather than structured evidence. FDA investigators consider this inadequate. The effectiveness evaluation must be structured, with criteria established before implementation, executed at a defined point, and documented with objective evidence.

Risk-Based Proportionality and the Connection Between Both Processes

QMSR's incorporation of ISO 13485:2016 brings an explicit risk-based approach to both corrective and preventive action. The level of investigation, the scope of corrective action, and the urgency of preventive action must all be calibrated to the risk level of the actual or potential failure being addressed. This proportionality is not optional language. It is a documented requirement that FDA investigators evaluate when reviewing CAPA records.

The two processes also intersect in a meaningful operational sense. When a corrective action resolves a nonconformity, the investigation findings and the nature of the root cause should feed back into the risk assessment and preventive action program. If a root cause investigation reveals a failure mode that the organization's current risk analysis did not adequately control, that finding becomes an input to a preventive action for all potentially affected processes or products. The corrective action process generated the intelligence; the preventive action process applies it systematically across the broader system.

A well-structured QMS under QMSR reflects this relationship explicitly. Corrective action records reference the risk assessment updates that followed. Preventive action records trace their input to a specific trend report, risk register output, or corrective action finding. Management review minutes document both processes and draw documented connections between them. When this architecture is present, the CAPA system demonstrates the systemic, risk-based quality thinking that QMSR was designed to codify.

Building a CAPA Program That Meets QMSR Requirements

Quality teams managing CAPA under QMSR need separate, documented procedures for corrective action and preventive action that each satisfy their respective ISO 13485:2016 clause requirements. The procedures do not need to be managed in entirely separate systems, but the workflows, record structures, and documentation outputs must be distinct and independently defensible.

The critical operational gap that QMSR exposes is in preventive action sourcing. Organizations that only initiate preventive actions from within a corrective action record, as a “prevent recurrence” checkbox, are not running a true preventive action program under clause 8.5.3. Preventive action has entirely different inputs: trend monitoring, supplier quality metrics, customer feedback analysis, internal audit outputs, and risk assessment findings. The function responsible for CAPA must have formal mechanisms to receive and analyze these data sources and convert them into documented, time-bound preventive action records.

From a process design standpoint, the key steps for corrective action are: initiation from a confirmed nonconformance source; containment where patient or product safety risk exists; formal root cause investigation using a documented methodology; determination and implementation of corrective actions; effectiveness verification with predefined criteria; and records submitted to management review. For preventive action, the key steps are: formal data collection and trend monitoring across QMS inputs; identification of potential failure conditions with documented analysis; risk evaluation to determine whether action is warranted; determination, implementation, and documentation of preventive actions; and effectiveness monitoring with formal management review reporting.

Cloudtheapp's CAPA module is built to support this separation with structural rigor. The platform maintains distinct workflows for corrective action and preventive action, each with dedicated record forms, role-based routing, configurable root cause analysis frameworks, and automated effectiveness verification scheduling. Quality Managers can configure each workflow independently to match existing SOPs without custom coding, and management review reporting is generated directly from CAPA record data.

Preparing for FDA Inspection Under the New Compliance Program

CAPA remains one of the most frequently cited areas in FDA inspections and Form 483 observations across both pharmaceutical and medical device manufacturers. The findings that carry the most enforcement weight are those that show systemic failure: ineffective root cause investigations; closed corrective actions where the nonconformity recurred; preventive action programs that are absent or undocumented; and effectiveness verifications that exist on paper but cannot be supported with objective evidence.

QMSR raises the compliance threshold by directly incorporating ISO 13485:2016 requirements. FDA investigators now have the full specificity of clauses 8.5.2 and 8.5.3 as the compliance benchmark. An organization that meets the general intent of CAPA but cannot demonstrate the specific documented outputs required by those clauses will accumulate observations.

The path to inspection readiness requires procedural clarity, documented execution, and a preventive action program that operates from real data inputs rather than as a formality embedded inside corrective action records. When these two processes are structurally distinct, their records are independently complete, and effectiveness verification is evidence-based and systematic, the CAPA program becomes one of the most defensible elements of the QMS rather than one of the most cited.

Cloudtheapp supports medical device and life sciences manufacturers in building compliant, inspection-ready CAPA systems as part of a fully validated, FDA-compliant eQMS, built on ISO 13485:2016 and 21 CFR Part 820 requirements from the ground up.

If your organization is working through QMSR compliance or building a CAPA program that meets the separate requirements of ISO 13485:2016 clauses 8.5.2 and 8.5.3, request a demo to see how the Cloudtheapp CAPA module operates in practice, or start a 30-Day Free Trial to explore the full platform in your own environment.

This post created by and appeared first on Cloudtheapp